Navigation Links
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
Date:6/3/2009

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer -

- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -

- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer -

- Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment -

- Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could Have Broad Anti-Cancer Utility -

TUSTIN, Calif., June 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects. Bavituximab is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Recently-reported data highlights from these studies include the following:

    -- Non-Small Cell Lung Cancer:  Bavituximab in Combination with
       Carboplatin and Paclitaxel
       In the Phase II trial evaluating bavituximab in combination with
       carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)
       patients with locally advanced or metastatic disease, 11 of 17, or
       almost 65% of evaluable patients in the initial cohort of 21 patients
       achieved an objective tumor response. These early results, which
       exceeded the pre-specified endpoint needed to expand the tria
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Brittenford ... independent schools, and other growing businesses across the United States, has announced that ... Resellers for the fifth consecutive year. , Based on company revenue and number ...
(Date:6/29/2015)... ... ... People across the country give their coworkers and families gifts all the time. From holiday ... how often do coworkers donate “life” to the husband of a coworker? For one VA ... (Wright-Thompson) told me her husband was on a donor list,” Glenshaw resident Kathi Dahl said. ...
(Date:6/29/2015)... ... June 29, 2015 , ... Assurex Health, a precision medicine ... and chronic pain conditions, has announced appointments to three key leadership roles, according ... Senior Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice President, Chief ...
(Date:6/29/2015)... , ... June 29, 2015 , ... The world’s fastest ... Virginia Aviation Museum to the Science Museum of Virginia. This iconic, supersonic stealth plane ... 2016. , “Suspending a supersonic jet from the ceiling of a historic train station ...
(Date:6/29/2015)... Detroit, MI (PRWEB) , ... June 29, 2015 , ... ... a perfect ten and have flawless skin all summer long and beyond. People ... 10 simple steps to slow the aging process, maintain an even skin tone, avoid ...
Breaking Medicine News(10 mins):Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
... Importance of Allergy Testing to Control Chronic ... ... Allergy and asthma specialists,from around the country will gather this week ... for,the Diagnosis and Management of Asthma. These guidelines are intended to,improve ...
... Studies have shown that surgery combined with Intraperitoneal Hyperthermic ... with peritoneal carcinoma (cancer of the lining of the ... cancer. , Researchers from Wake Forest University School of ... use of IPHC in treating peritoneal cancer that has ...
... WASHINGTON, March 14 Last night, the U.S.,Senate ... for,Legislative and Public Affairs for the U.S. Agency ... Bureau for Legislative and Public Affairs, Grieco will,manage ... public,and constituent groups to communicate the agency,s mission, ...
... scientists suggests a safer way to treat medulloblastoma, a ... found that one of the brains signaling pathways inhibits ... , The researchers discovered that three proteins, designated BMP2, ... and induced the malignant cells to develop into normal ...
... moved from colon, appendix , , FRIDAY, March 14 (HealthDay ... spread to the peritoneum -- the membrane lining the ... of chemotherapy can improve survival rates, Wake Forest University ... two Wake Forest studies presented at this week,s annual ...
... team of researchers in Bedford, Mass. has developed a ... detect signs of Alzheimer,s disease. , In the ... by the Optical Society of America, the team describes ... taken from different autopsies and correctly identified which samples ...
Cached Medicine News:Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Researchers study new drug and indications for heated chemotherapy treatment 2Health News:Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 2Health News:St. Jude finds signaling system that halts the growth of a childhood brain cancer 3Health News:Combo Treatment Ups Survival When Cancer Spreads to Abdominal Lining 2Health News:Researchers use light to detect Alzheimer's 2Health News:Researchers use light to detect Alzheimer's 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: